🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 47 of 757 · Phase 3 first, then by program name

  1. Dupilumab SAR231893

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    1 trial

  2. Dupilumab SAR231893

    Regeneron UK Limited

    Allergic Fungal Rhinosinusitis

    phase 3 small molecule completed

    1 trial

  3. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 3 small molecule completed

    1 trial

  4. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  5. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  6. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

    phase 3 small molecule completed

    2 trials

  7. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    2 trials

  8. Dupilumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  9. Dupilumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  10. Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen

    Pharma Mar S.A.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  11. Durvalumab

    Arcus Biosciences

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. Duvakitug

    Teva Pharma GmbH

    Ulcerative Colitis

    phase 3 small molecule active

    2 trials

  13. Duvakitug

    Teva Pharma GmbH

    Crohn's Disease

    phase 3 small molecule active

    2 trials

  14. Duvakitug, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  15. Duvakitug, matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  16. Dynepo (Epoetin delta)

    Takeda Pharmaceuticals International AG

    Anemia

    phase 3 small molecule terminated

    1 trial

  17. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen Pharma

    Chronic migraine

    phase 3 small molecule active

    1 trial

  18. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen Pharma

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  19. E004 (Epinephrine Inhalation Aerosol) HFA-MDI

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  20. E7777 9 mcg/kg

    CITIUS ONCOLOGY, INC.

    Persistent or Recurrent Cutaneous T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  21. EADM

    China SXT Pharmaceuticals

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  22. EB-101

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  23. EB-101 Surgical application of RDEB wounds

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  24. EBVALLO

    Pierre Fabre Medicament

    Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources